Krystal Biotech, Inc. (KRYS) vs Protagonist Therapeutics, Inc. (PTGX)
Krystal Biotech, Inc. and Protagonist Therapeutics, Inc. are both Biotechnology companies. Krystal Biotech, Inc. is the larger, with a market value of $10.2B against $8.9B — 1.1× the size. Krystal Biotech, Inc. trades at the lower P/E: 41.9× against 117×. Protagonist Therapeutics, Inc. grew revenue faster over the last twelve months: 34.8% against 22.6%. Krystal Biotech, Inc. has the higher net margin (54.8% vs 29.4%) and the lower return on invested capital (24.1% vs 61.8%). Across the 19 metrics below, Krystal Biotech, Inc. leads on 15 and Protagonist Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | KRYS | PTGX | Biotechnology median |
|---|---|---|---|
| Gross margin | 94.64% | 100.00% | 65.16% |
| Operating margin | 44.89% | 20.69% | 0.00% |
| Net margin | 54.82% | 29.40% | 0.00% |
| Free cash flow margin | 58.52% | 46.31% | 0.00% |
| Return on equity | 20.12% | 10.98% | (57.72%) |
| Return on assets | 18.30% | 10.34% | (49.22%) |
| Return on invested capital | 24.07% | 61.84% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack